Version 1
: Received: 13 November 2019 / Approved: 14 November 2019 / Online: 14 November 2019 (11:27:55 CET)
Version 2
: Received: 16 December 2019 / Approved: 16 December 2019 / Online: 16 December 2019 (11:25:16 CET)
How to cite:
Berlina, A.N.; Zherdev, A.V.; Dzantiev, B.B. Monitoring Antibiotics and Inflammatory Markers in Human Blood: Impact in Choice of Antibiotic Therapy and Used Methods. Preprints2019, 2019110163. https://doi.org/10.20944/preprints201911.0163.v2
Berlina, A.N.; Zherdev, A.V.; Dzantiev, B.B. Monitoring Antibiotics and Inflammatory Markers in Human Blood: Impact in Choice of Antibiotic Therapy and Used Methods. Preprints 2019, 2019110163. https://doi.org/10.20944/preprints201911.0163.v2
Berlina, A.N.; Zherdev, A.V.; Dzantiev, B.B. Monitoring Antibiotics and Inflammatory Markers in Human Blood: Impact in Choice of Antibiotic Therapy and Used Methods. Preprints2019, 2019110163. https://doi.org/10.20944/preprints201911.0163.v2
APA Style
Berlina, A.N., Zherdev, A.V., & Dzantiev, B.B. (2019). Monitoring Antibiotics and Inflammatory Markers in Human Blood: Impact in Choice of Antibiotic Therapy and Used Methods. Preprints. https://doi.org/10.20944/preprints201911.0163.v2
Chicago/Turabian Style
Berlina, A.N., Anatoly V. Zherdev and Boris B. Dzantiev. 2019 "Monitoring Antibiotics and Inflammatory Markers in Human Blood: Impact in Choice of Antibiotic Therapy and Used Methods" Preprints. https://doi.org/10.20944/preprints201911.0163.v2
Abstract
In the modern world, the problem of antibiotic therapy is acute. Despite the diversity of existing antibiotic drugs, their efficacy decreases as new, resistant forms of pathogenic microorganisms emerge. It is extremely difficult to control such processes and even more difficult to treat severe bacterial infections. In such situations, an individual approach to each patient is required and physicians need parameters to estimate the efficacy of antibiotic therapy. This review discusses the significance of monitoring the content of antibiotics in the blood for this purpose, in combination with the content of inflammatory markers, such as C-reactive protein and procalcitonin. The basic principles of antibiotic therapy, and factors in the resistance of microorganisms to antibiotics, are examined. Approaches to assess the efficacy of antibiotic therapy, as well as methods to detect antibiotics and inflammatory markers in the blood of patients, and comparative assessment of their capabilities and limitations, are described.
Keywords
individual therapy; metabolism of antibiotics; dosage choice; inflammation; biomarkers
Subject
Medicine and Pharmacology, Pharmacy
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
16 December 2019
Commenter:
Boris Dzantiev
Commenter's Conflict of Interests:
Author
Comment:
We have received the comment on our review:
"I was reviewing this article given the noted information for omadacycline. In my reading I noticed that within Table 5 the Cmin for omadacycline is incorrectly listed as 16.0 +/- 3.5 this is the half-life which it is appropriately noted in the next column. The Cmin should be listed as 0.28 +/- 0.10 as per the reference used Gotfried et al. 2017. Antimicrob Agents Chemother 61:e01135-17. https://doi.org/10.1128/AAC.01135-17.
Lastly Table 6 appears to be inappropriately named as ". Pharmacokinetic parameters for omadacycline and tigecycline in plasma, administered intravenously for 30 min, at doses of 100 mg and 50 mg, respectively" which is the name of Table 5".
In accordance to the comment of the reviewer, we changed the title of Table 6 and changed the Cmin of omadacycline in Table 5.
Commenter: Boris Dzantiev
Commenter's Conflict of Interests: Author
"I was reviewing this article given the noted information for omadacycline. In my reading I noticed that within Table 5 the Cmin for omadacycline is incorrectly listed as 16.0 +/- 3.5 this is the half-life which it is appropriately noted in the next column. The Cmin should be listed as 0.28 +/- 0.10 as per the reference used Gotfried et al. 2017. Antimicrob Agents Chemother 61:e01135-17. https://doi.org/10.1128/AAC.01135-17.
Lastly Table 6 appears to be inappropriately named as ". Pharmacokinetic parameters for omadacycline and tigecycline in plasma, administered intravenously for 30 min, at doses of 100 mg and 50 mg, respectively" which is the name of Table 5".
In accordance to the comment of the reviewer, we changed the title of Table 6 and changed the Cmin of omadacycline in Table 5.